ArticleOPEN ACCESS

CyBorD: Stellar response rates in AL amyloidosis

Blood
DOI: 10.1182/blood-2012-03-413112
50Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In two independent retrospective studies, Mikhael et al and Venner et al report unprecedentedly high hematologic response rates, 94% and 81%, including complete response (CR) in 71% and 42%, respectively, to the combination of cyclophosphamide-bortezomib-dexamethasone in patients with either naive or relapsed light chain (AL) amyloidosis.

Cite

CITATION STYLE

APA

Merlini, G. (2012, May 10). CyBorD: Stellar response rates in AL amyloidosis. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2012-03-413112

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free